Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression of two Ewing sarcoma cell lines (A-673, ES7), treated with triapine (3-AP) or vehicle (DMSO)

ABSTRACT: Gene expression of two Ewing sarcoma cell lines (A-673, ES7), treated with triapine (3-AP) or vehicle (DMSO)

PROVIDER: PRJNA700866 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression of two Ewing sarcoma cell lines (A-673, ES7), treated with triapine (3-AP) or vehicle (DMSO)

Project description:This dataset comprises transcriptome data of two Ewing sarcoma cell lines (A-673, ES7) after treatment with triapine (3-AP) or vehicle (DMSO) for 72h.

2021-08-03 | GSE166419 | GEO

Gene expression of two Ewing sarcoma cell lines (A-673, ES7), transduced with inducible shControl or two different shRNA against RRM2

Project description:This dataset comprises transcriptome data of two Ewing sarcoma cell lines (A-673 and ES7) after knockdown of the gene RRM2

2021-08-03 | GSE166415 | GEO

Reciprocal regulation of extracellular matrix proteins by EWS-FLI1 and AP-1 in Ewing sarcoma cells

Project description:Ribonucleotide reductase (RNR) is the rate limiting enzyme in the synthesis of deoxyribonucleotides and the target of multiple chemotherapy drugs, including gemcitabine and hydroxyurea. In previous work, we identified that inhibition of RNR in Ewing sarcoma tumors upregulates the expression levels of multiple members of the activator protein-1 (AP-1) transcription factor family, including c-Jun and c-Fos, and downregulates the expression of c-Myc. However, the broader functions and downstream targets of AP-1, which are highly context- and cell-dependent, are unknown in Ewing sarcoma tumors. Consequently, in this work, we used genetically defined models, transcriptome profiling, and gene set enrichment analysis to identify that AP-1 and EWS-FLI1, the driver oncogene in most Ewing sarcoma tumors, reciprocally regulate the expression of multiple extracellular matrix proteins, including fibronectins, integrins, and collagens. AP-1 expression in Ewing sarcoma cells also drives, coincident with these perturbations in gene and protein expression, changes in cell morphology and phenotype. Furthermore, we also identified that the EWS-FLI1 oncoprotein dysregulates the expression of multiple AP-1 proteins, aligning with previous reports demonstrating genetic and physical interactions between EWS-FLI1 and AP-1. Overall, these results provide novel insight into the distinct, EWS-FLI1-dependent features of Ewing sarcoma tumors and identify a novel, reciprocal regulation of extracellular matrix components by EWS-FLI1 and AP-1.

2024-09-30 | GSE263503 | GEO

LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

Project description:LX-2 cells were pretreated with CM272 (400nM) or vehicle (0.01%DMSO) for 24 hours followed by incubation of TGFβ1 (5ng/ml) for another 24 hours.

2019-10-29 | GSE139504 | GEO

FOXO-inhibited iPSC-derived cardiomyocytes compared against DMSO vehicle controls.

Project description:Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes cultured in 3-dimensional suspension culture were treated with AS1842856 FOXO-inhibitor (n=3 independent wells) or DMSO vehicle control (n=3 independent wells). Total RNA was isolated from each well and utilized for RNA sequencing.

2024-08-09 | GSE252627 | GEO

FOXO-inhibited iPSC-derived cardiomyocytes compared against DMSO vehicle controls.

Project description:FOXO-inhibited iPSC-derived cardiomyocytes compared against DMSO vehicle controls.

| PRJNA1061534 | ENA

Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

Project description:We use RNAseq to examine gene expression changes in A375 cells after treatment with A-366 versus DMSO (vehicle) of mScarlet tagged H3.3(wildtype) vs. H3.3(K9M)

2022-01-02 | GSE192612 | GEO

Enhanced RNA Interactome capture (eRIC) and RNA Interactome capture (RIC) of Jurkat cells (DSMZ, ACC-282) exposed to 0.5mM DMOG or vehicle (DMSO) for 6 hours.

Project description:1.0 â€“ 1.3 x 10e8 proliferating Jurkat cells at a density of about 1-1.5 x 10e6 cells/mL were employed per sample. Cells were incubated with 0.5mM DMOG (Cayman Chemical Company, 71210) or an equivalent volume of Dimethyl Sulfoxide (DMSO) (vehicle, Merck 1.02950.0500). The DMSO concentration in the medium was 0.023% v/v. Cells were irradiated or not with 254 nm UV light and subjected to eRIC or RIC to determine the RNA-bound proteome. Data correspond to two biologically independent experiments.

2018-09-03 | PXD010942 | Pride

Expression profiling of Ewing sarcoma cell lines exposed to 5nM Pladienolide B (PlaB) for 24 hours

Project description:Identification of genes and pathways altered by PlaB, a bacterial natural product that acts as a spliceosome modulator by targeting the SF3b subunit of the spliceosome SKNMC, TC32, TC71, and RD-ES Ewing sarcoma cell lines were treated with 0.1% (v/v) DMSO vehicle or 5nM PlaB for 24 hours. Three samples in each group were analyzed.

2016-01-15 | E-GEOD-67548 | biostudies-arrayexpress

LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

Project description:LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

| PRJNA579991 | ENA